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ttp://dx.doi.org/10.1016/j.ajpath.2013.06.034Macrophages are essential for the efﬁcient healing of numerous tissues, and they contribute to impaired
healing and ﬁbrosis. Tissue repair proceeds through overlapping phases of inﬂammation, proliferation,
and remodeling, and macrophages are present throughout this progression. Macrophages exhibit
transitions in phenotype and function as tissue repair progresses, although the precise factors regu-
lating these transitions remain poorly deﬁned. In efﬁciently healing injuries, macrophages present
during a given stage of repair appear to orchestrate transition into the next phase and, in turn, can
promote debridement of the injury site, cell proliferation and angiogenesis, collagen deposition, and
matrix remodeling. However, dysregulated macrophage function can contribute to failure to heal or
ﬁbrosis in several pathological situations. This review will address current knowledge of the origins and
functions of macrophages during the progression of tissue repair, with emphasis on skin and skeletal
muscle. Dysregulation of macrophages in disease states and therapies targeting macrophage activation
to promote tissue repair are also discussed. (Am J Pathol 2013, 183: 1352e1363; http://dx.doi.org/
10.1016/j.ajpath.2013.06.034)Supported by NIH grant R01GM092850 (T.J.K.), American College of
Sports Medicine Doctoral Student Research grant 2011-03604-00-00
(M.L.N.), and University of Illinois at Chicago Graduate College Dean’s
Scholar Award (M.L.N.).Macrophages are essential to efﬁcient healing of numerous
tissues,1e5 and they also contribute to impaired healing and
ﬁbrosis.6e9 At different stages of the healing process,
macrophages can promote debridement of the injury site,
cell proliferation, angiogenesis, collagen deposition, and
matrix remodeling, but improper regulation of any of these
macrophage functions can also impair healing. These
seemingly contradictory roles of macrophages are likely
because of the ability of macrophages to assume a wide
spectrum of functional phenotypes determined by their
microenvironment and possibly by lineage, although the
exact factors responsible for regulating macrophage
phenotype in vivo remain poorly deﬁned.10e12
Although macrophages in vivo rarely exhibit exactly the
same phenotypes as cultured cells,12,13 in vitro studies have
deﬁned convenient reference points along the nearly inﬁnitestigative Pathology.
.spectrum of possible macrophage phenotypes.10,14 Proin-
ﬂammatory M1 macrophages are produced by exposure to
interferon (IFN)g and tumor necrosis factor (TNF)a or
bacterial products, which activate MyD88 and NF-kB. M2a
macrophages are produced by exposure to IL-4 or IL-13,
which signal through the common receptor, IL-4 receptor
a, and subsequent STAT6 activation; M2a macrophages
have the potential to be proﬁbrotic. Finally, immune regu-
latory functions have been postulated for macrophages of
the M2b phenotype produced by combined stimulation with
bacterial products and immune complexes, and for similar
Macrophages Orchestrate Tissue RepairM2c phenotype produced by exposure to IL-10 or gluco-
corticoids, which act, in part, via inhibition of STAT1 and
NF-kB.10,14 During tissue repair, inﬁltrating macrophages
do not appear to conform to in vitroedeﬁned M1 and M2
categories12,13,15; however, knowledge about the regulation
and function of different macrophage phenotypes has the
potential to yield new therapies for improving healing.
This review will address the changing functions and phe-
notypes of macrophages during the progression of tissue repair,
with emphasis on healing of skin and skeletal muscle. We also
endeavor to point out gaps in the literature, particularly where
macrophage function inferred from in vitro studies has not yet
been conﬁrmed in vivo. In addition, macrophage dysregulation
during impaired healing will be discussed, as will potential
therapies based on modulation of macrophage function.
Origin of Tissue Macrophages after Injury
Under homeostatic conditions, maintenance of the resident
macrophage population occurs by either local proliferation or
recruitment and differentiation of bloodmonocytes, dependent
on the tissue in question.11,16 After an inﬂammatory insult,
however, macrophages that accumulate at sites of injury
appear to be largely derived from circulating monocytes,11,16
although there is also evidence that resident macrophages of
the skin or of the muscle epimysium may contribute to the
inﬂammatory inﬁltrate and/or participate in recruitment of
circulating monocytes.17,18 In addition, although the increase
in F4/80 expression on monocytes after tissue inﬁltration is
generally presumed to indicate differentiation to macrophages,
it remains unclear whether these cell types are functionally
distinct during in vivo tissue repair, despite their well-deﬁned
differences in vitro and during homeostasis. Because of this
uncertainty, the term monocyte/macrophage will be used in
this review whenever the distinction is unclear, particularly
during the inﬂammatory phase of tissue repair.
Importance of Blood Monocyte Recruitment
Numerous studies have demonstrated the importance of
circulating monocyte recruitment for macrophage accumula-
tion after injury. Tissue inﬁltration by latex bead-labeled blood
monocytes is observed after muscle injury in mice,19 and
depletion of circulating monocytes by i.v. or i.p. delivery of
clodronate-containing liposomes (which are not expected to
deplete muscle resident macrophages20) greatly reduces mus-
cle macrophage accumulation3,21; these data indicate that
macrophages that accumulate in injured muscle are mainly
derived from blood monocytes. In mouse skin wounds,
contribution of blood monocytes to the wound inﬁltrate is
suggested by the sharp decrease in circulating CCR2hi/Ly6Chi
monocytes that occurswithin 6 hours after injury.22 In addition,
long-term treatment of mice with anti–colony-stimulating
factor 1 receptor antibody depletes residentmacrophages of the
skin and other tissues but does not alter monocyte/macrophage
recruitment to the nasal epithelium after wounding. This againThe American Journal of Pathology - ajp.amjpathol.orgindicates that circulating monocytes, rather than resident
macrophages, are the primary contributors to the inﬂammatory
inﬁltrate.23 However, in support of a potential contribution of
resident macrophages, substantial proliferation of Langerhans
cells is observed in a mouse model of atopic dermatitis.17 One
might speculate that the relative importance of blood mono-
cytes versus resident macrophages to the inﬂammatory inﬁl-
trate may depend on the mode and/or severity of injury.
Monocyte Subsets
In mice, blood monocytes can be segregated into two major
subsets based on high or low expression of Ly6C.11 In humans,
threemonocyte populations can be identiﬁed based on differing
levels of CD14 and CD16.16 There may be an approximate
correspondence between mouse Ly6Chi and human CD14hi/
CD16neg monocytes, and between mouse Ly6Clow and human
CD14low/CD16hi monocytes, although the true degree of sim-
ilarity remains to be determined.16 Monocytes of different
subsets appear to be specialized for different functions and may
be predisposed to differentiate into either dendritic cells or
macrophages of different phenotypes.11,16,24 Although
macrophage phenotype is heavily dependent on external
stimuli, such as cytokine exposure,10 a contribution of mono-
cyte lineage to macrophage phenotypic determination has also
been suggested.16 In particular, Ly6Chi monocytes may be
predisposed to inﬂammatory and phagocytic functions,
whereas Ly6Clow monocytes may be predisposed to anti-
inﬂammatory and reparative functions,24 although this matter
bears further investigation. In addition, there is some debate as
to whether circulating Ly6Chi and Ly6Clow monocytes repre-
sent truly separate lineages or whether Ly6Clow monocytes are
produced by maturation of Ly6Chi cells that return to the bone
marrow from the circulation.11,16
A similar question of lineage arises for monocytes/mac-
rophages in injured tissue (Figure 1). After injury to most
tissues, including skin,6,22 skeletal muscle,19 and heart,24
Ly6Chi monocytes are the ﬁrst to inﬁltrate the injured tis-
sue, and these are gradually replaced by Ly6Clow mono-
cytes/macrophages as repair progresses. In injured mouse
skeletal muscle, Ly6Clow monocytes/macrophages appear to
arise from in situ conversion of early-inﬁltrating Ly6Chi
monocytes, as demonstrated by latex bead labeling of blood
monocyte subsets.19 The i.v. injection of latex beads labels
circulating Ly6Clow, but not Ly6Chi, monocytes, and in this
case, the latex label is not detected in injured muscle. In
contrast, when circulating Ly6Chi monocytes are labeled
instead (requiring prior clodronate-mediated depletion of
blood monocytes), both the Ly6Chi and Ly6Clow pop-
ulations within the injured muscle contain the latex label.19
These results demonstrate that Ly6Clow monocytes/macro-
phages in injured muscle are derived from an in situ switch
of early-invading Ly6Chi monocytes, rather than sequential
invasion of distinct blood monocyte populations. In mouse
skin wounds, Ly6Chi monocytes invade rapidly after
injury22; however, whether the Ly6Clow population, which1353
Figure 1 Models of monocyte recruitment
during tissue repair. Left panel: In mouse skeletal
muscle, circulating Ly6Chi monocytes are recruited
via CCL2/CCR2, then converted to Ly6Clow in situ.
Right panel: After myocardial infarction in mice,
the heart sequentially recruits Ly6Chi, then Ly6Clow,
blood monocytes via CCL2/CCR2 and CX3CL1/
CX3CR1, respectively. The mechanisms of mono-
cyte recruitment in skin remain to be determined.
Novak and Kohaccumulates later, derives from its circulating counterpart or
from conversion of Ly6Chi monocytes within the tissue has
not been extensively investigated. In situ conversion in both
skin and skeletal muscle is suggested by the fact that, in
contrast to the relatively discrete Ly6C high- and low-
expressing subsets observed in blood, tissue monocytes/
macrophages with a range of intermediate Ly6C expression,
in addition to high and low expressers, are often observed at
intermediate time points after injury.6,19,22,25
In contrast, when Ly6Chi or Ly6Clow monocytes are labeled
ex vivo and delivered i.v. to mice after myocardial infarction,
the heart recruits the two monocyte populations in a sequential
manner: exogenous Ly6Chi monocytes are preferentially
recruited at 1 day after infarction, whereas at 4 days, recruit-
ment is primarily from the Ly6Clow compartment.24 Further
studies will be necessary to determine whether the divergent
results obtained in skeletal versus cardiac muscle19,24 are
merely representative of the different experimental protocols
used, or whether these two types of striated muscle have truly
evolved distinct mechanisms of obtaining Ly6Clow mono-
cytes/macrophages during repair. A potentially revealing
study could use experiments reciprocal to those previously
published (ie, determine whether in situ conversion is still
favored in skeletal muscle when the exogenous monocyte
delivery protocol is used, and whether the latex labeling pro-
tocols demonstrate sequential recruitment in the heart).
Mechanisms of Monocyte Recruitment
The major chemokine systems responsible for recruitment of
Ly6Chi or Ly6Clow monocytes from blood appear to be1354chemokine ligand (CCL) 2/CCR2 and CX3CL1/CX3CR1,
respectively,11 and manipulation of these systems may shed
light on the issue of sequential monocyte recruitment versus
in situ conversion in various tissues. In injuredmouse skeletal
muscle, skin, and heart, CCR2 is required for early Ly6Chi
monocyte/macrophage accumulation.22,24,26 Interestingly,
and in support of distinct mechanisms of Ly6Clow monocyte
accumulation in heart versus skeletal muscle, genetic dis-
ruption of CCR2 reduces accumulation of both Ly6Chi and
Ly6Clow monocytes in injured skeletal muscle,26 but does not
alter recruitment of Ly6Clow monocytes to the heart after
myocardial infarction.24 CCR2-null mice also exhibit re-
duced monocyte/macrophage accumulation in skin wounds
at 2 and 4 days after injury (when Ly6Chi monocytes are
dominant), but not at 7 days (when Ly6Clow monocytes/
macrophages are themajor population).22Although this study
did not speciﬁcally address recruitment of different monocyte
subsets in the absence of CCR2, these data may suggest that
skin wounds recruit blood monocytes in sequential waves by
separate mechanisms, similar to infarcted heart. CCR2 is also
important for egress of Ly6Chi monocytes from bone marrow
to the blood,26 and this caveat should be considered when
interpreting studies using disruption of CCR2, because de-
creased monocyte accumulation in tissues could be caused, in
part, by a reduction of available monocytes in circulation,
with or without a defect in themechanism of recruitment from
the blood to the injured tissue.
Ly6Clow monocytes express the chemokine receptor
CX3CR1, which is believed to be important for their
recruitment from the blood.11 In mice lacking CX3CR1,
accumulation of Ly6Clow (but not Ly6Chi) monocytes isajp.amjpathol.org - The American Journal of Pathology
Macrophages Orchestrate Tissue Repairreduced in infarcted heart, suggesting that their recruitment
from blood is impaired.24 Macrophage accumulation in skin
wounds is also reduced in mice lacking CX3CR1.
27 How-
ever, because CX3CL1/CX3CR1 interaction is also an
important anti-apoptotic stimulus,28 an alternate interpreta-
tion of these data could be that monocyte/macrophage sur-
vival may be reduced in the absence of CX3CR1. To the best
of our knowledge, the role of CX3CL1/CX3CR1 in monocyte/
macrophage accumulation in injured skeletal muscle has not
been elucidated, although this system may not be involved
in recruitment to skeletal muscle because Ly6Clow mono-
cytes/macrophages in these injuries appear to be derived
from in situ switching of Ly6Chi monocytes recruited by
CCL2/CCR2.19,26
In summary, monocytes/macrophages that accumulate in
injured skin, skeletal muscle, and heart appear to be derived
mainly from circulating monocytes, although resident
macrophages may contribute by either local proliferation or
assisting in blood monocyte recruitment.17e19,22,24 Ly6Chi
monocytes are recruited early after injury to all three tissues,
mediated in part by CCL2/CCR2.22,26 In skeletal muscle,
accumulation of Ly6Clow monocytes/macrophages appears
to result from in situ conversion of Ly6Chi monocytes.19 In
contrast, infarcted cardiac muscle appears to recruit these
monocyte subsets sequentially from the circulation.24
However, it has not yet been determined whether Ly6Clow
monocytes/macrophages in skin wounds arise from Ly6Clow
blood monocytes or from in situ conversion of Ly6Chi
monocytes. The precise role of CX3CL1/CX3CR1 in
monocyte/macrophage accumulation also remains to be
determined, because this system could potentially contribute
to monocyte recruitment, survival, or both.27,28 Finally and
perhaps most important, the kinetics and mechanisms of
recruitment of human blood monocyte populations to
injured tissues remain to be elucidated.Monocyte/Macrophage Functions during the
Progression of Tissue Repair
Although the precise origins of tissue repair monocytes/mac-
rophages remain a matter of active investigation, their pres-
ence is essential for orchestration of efﬁcient healing.1e5
Across numerous tissues, repair progresses through over-
lapping phases of inﬂammation, proliferation, and remodeling.
The kinetics of each phase depend on the severity of injury and
can be altered by factors such as infection, advanced age, or
diabetes.6,7,29e31 However, in commonly used experimental
models, the inﬂammatory phase is generally limited to the ﬁrst
few days after injury; the proliferative phase begins within
days after injury and peaks within 1 week after injury; and the
remodeling phase begins as proliferation starts to subside, and
can last for months or more. Macrophages appear to be
important orchestrators and effectors of this progression,
altering their function and phenotype to meet the needs of the
healing tissue (Figure 2).The American Journal of Pathology - ajp.amjpathol.orgThe Inﬂammatory Phase
Within hours after acute injury, inﬂammatory cells,
including neutrophils and monocytes, begin to accumulate
at the affected site. In common experimental models using
healthy young male mice, neutrophil accumulation peaks
around day 1 and returns to uninjured levels by days 5 to 10
after skeletal muscle injury by toxin injection32,33 or after
skin wounding.2,34 Macrophage accumulation peaks some-
what later, around days 3 to 7, and declines signiﬁcantly by
days 10 to 14, although low levels of macrophage accu-
mulation may persist for weeks.1,2,19,33e35 Inﬂammatory
cell accumulation appears to follow a similar time course
after acute injury in humans.36,37
One of the major functions of monocytes/macrophages
during the inﬂammatory phase appears to be removal of
damaged tissue. In efﬁciently healing muscle injuries in
mice, necrotic debris is cleared well within the ﬁrst week after
injury, in concert with increasing monocyte/macrophage
accumulation.21,32,38 However, whenmonocytes/macrophages
are prevented from accumulating in toxin-injured mouse
muscle (whether by direct depletion of blood monocytes or
tissue macrophages,3,19,21 or through deﬁciencies in key
chemotactic pathways21,38), necrotic myoﬁbers persist within
the injured muscle unless or until monocyte/macrophage
accumulation is eventually restored. Similarly, in guinea pig
skin wounds, depletion of wound macrophages by hydro-
cortisone and anti-macrophage serum results in defective
wound debridement.39
In addition to clearing necrotic debris, tissue repair macro-
phages are capable of inducing apoptosis of40 and phagocy-
tosing neutrophils both in vivo and ex vivo,39,41 a mechanism
that may contribute to the resolution of the inﬂammatory phase
and the transition to the proliferative phase of healing. How-
ever, the actual necessity of macrophages for apoptotic cell
clearance in vivo is less certain, because the effect of macro-
phage depletion on neutrophil accumulation appears to be
dependent on the tissue and/or method of macrophage deple-
tion. In mouse skeletal muscle injuries, neutrophil accumula-
tion is largely unaffected, or at most slightly and transiently
increased, by reduction of monocyte/macrophage accumula-
tion, whether by macrophage colony-stimulating factore
blocking antibody or by deﬁciency of CCR2/CCL2 or other
chemotactic pathways.21,26,38,42,43 In skin wounds, the effect
of macrophage depletion on neutrophil accumulation appears
to be highly dependent on the experimental protocol used. In
the CD11bediphtheria toxin receptor (DTR) mouse model [in
which expression of the diphtheria toxin (DT) receptor under
the control of the CD11b promoter allows inducible macro-
phage depletion by administration of DT], macrophage
depletion does not alter the time course of neutrophil accu-
mulation and resolution in murine skin wounds,2 suggesting
that macrophagesmay be dispensable for neutrophil clearance.
In support of the necessity of macrophages for neutrophil
clearance, however, prolonged neutrophil accumulation in
wounds is observed when macrophages are depleted by1355
Figure 2 Phases of tissue repair. Efﬁcient tissue repair occurs in overlapping phases of inﬂammation, proliferation, and remodeling. Monocytes/
macrophages (Mps) are present during all phases of repair and orchestrate timely progression of healing. Macrophages of the inﬂammatory phase phagocytose
dead tissue and promote proliferation of endothelial cells (ECs) and skeletal muscle myoblasts (Mbs). Effects on ﬁbroblast (Fb) proliferation and collagen
production appear to be tissue dependent. Macrophages of the proliferative phase promote vascular maturation, myoﬁber hypertrophy, and collagen pro-
duction and remodeling.
Novak and Kohhydrocortisone plus anti-macrophage serum in guinea pigs,39
or by administration of DT to heterozygous transgenic
LysM-Cre/DTR mice (in which DT receptor expression is
induced by Cre recombinase in LysM-expressing cells).44
These contrasting results are likely due to the differ-
ent macrophage depletion protocols used. Hydrocortisone/
anti-macrophage serum depletes blood monocytes and pre-
vents wound monocyte/macrophage accumulation, whereas
the timing of DT administration used by Mirza et al2 in the
CD11b-DTR model likely allows for initial inﬂux of blood
monocytes to the wound and appears to deplete only mature,
F4/80þ wound macrophages. Thus, it is possible that recently
inﬁltrated wound monocytes, rather than differentiated mac-
rophages, may be the primary effectors of neutrophil clear-
ance. Alternately, it is possible that a failure of neutrophil
clearance in DT-treated CD11b-DTR mice could be masked
by secondary necrosis of apoptotic neutrophils, leading to a
lack of detection of neutrophils in tissue sections.
In addition to clearing dead or dying cells and tissue,
monocytes/macrophages of the inﬂammatory phase produce
inﬂammatory cytokines that may help to orchestrate the
healing response. In both skin and skeletal muscle injuries,
early monocytes/macrophages secrete cytokines such as
IL-1, TNFa, and IL-6,22,25,45 although the relative importance1356of cytokine production by monocytes/macrophages versus
other cell types, such as neutrophils or tissue resident cells,
remains to be determined. Although prolonged or excessive
inﬂammatory cytokine levels contribute to impaired skin
wound healing and to muscle wasting or damage,7,8,46,47 IL-6
and TNFa are essential to efﬁcient healing when conﬁned to
their proper time in the early days after injury to rodent skin
or skeletal muscle.48e52 Potential beneﬁcial effects of IL-6
and TNFa include regulation of proliferation of keratino-
cytes, myoblasts, and ﬁbroblasts.53e60 In contrast, IL-1 ap-
pears to be dispensable for skin wound healing in mice,
and genetic or pharmacological disruption of IL-1 reduces
ﬁbrosis without affecting the tensile strength of the repaired
skin.61 To the best of our knowledge, the role of IL-1 in repair
of acute skeletal muscle injuries has not been extensively
investigated.
Despite the predominantly proinﬂammatory cytokine
proﬁle of monocytes/macrophages during the early inﬂam-
matory phase, these cells are not fully analogous to
in vitroedeﬁned M1 macrophages.12,13 For instance, early
mouse skin wound monocytes/macrophages express high
levels of arginase-1 and Ym1,22,45 which are more commonly
associated with M2a activation.10,62 Arginase-1 and Ym1
have been postulated to promote collagen production and cellajp.amjpathol.org - The American Journal of Pathology
Macrophages Orchestrate Tissue Repairproliferation and migration, although whether macrophage-
derived arginase-1 and Ym1 actually perform these func-
tions during tissue repair remains unclear.63,64 Early skin
wound monocytes/macrophages also produce vascular
endothelial growth factor (VEGF) and thereby promote
granulation tissue formation and angiogenesis.22
Monocytes/macrophages of the inﬂammatory phase
appear to orchestrate the transition to the proliferative phase
of healing. Depletion of monocytes/macrophages during the
inﬂammatory phase reduces granulation tissue formation and
cell proliferation in mouse skin wounds1,6 and prevents for-
mation of new myoﬁbers in injured muscle,19,21 although the
exact mechanisms by which monocytes/macrophages regu-
late these processes remain to be determined. In culture, M1
or M1-like macrophages can promote myoblast and ﬁbro-
blast proliferation, and suppress myoblast differentiation and
fusion, in part through secretion of proinﬂammatory
cytokines.19,55,65e68 Because the cytokine proﬁle of tissue
repair macrophages during the inﬂammatory phase appears
to be similar, although not identical, to that of M1 macro-
phages,12,13 cytokine production may be one mechanism by
which monocytes/macrophages of the inﬂammatory phase
initiate a transition to the proliferative phase.
Interestingly, collagen deposition in skin wounds appears to
be controlled by monocytes/macrophages of the inﬂammatory
phase, rather than macrophages of later phases.1,69 Although
pronounced accumulation of collagen protein in mouse skin
wounds can take up to 1 week,2 transcription of col1a1 and
col1a2 is up-regulated as early as 2 to 3 days after injury.34,69
Both early mRNA and later protein levels of collagen are
reduced by depletion of monocytes/macrophages during
the inﬂammatory phase, resulting in delayed healing but
reduced scar formation.1,2,69 In contrast, prevention of muscle
macrophage accumulation by macrophage colony-stimulating
factor receptoreblocking antibody increases ﬁbrosis in injured
mouse skeletal muscle,42 suggesting that the role of
inﬂammatory-phase monocytes/macrophages in collagen
depositionmaydiffer between skin and skeletalmuscle injuries.
The Proliferative Phase
Cell proliferation begins in the early days after injury to
mouse skin and skeletal muscle, peaks around day 5, and
persists at low levels until at least day 10 to 12,70,71 a time
course remarkably similar to that of macrophages. During
this phase of healing, skeletal muscle satellite cells are
activated, and proliferation, differentiation, and fusion of
these stem cells allow eventual restoration of muscle
structure and contractile function.72 Similarly in skin, ker-
atinocyte proliferation and migration allow reepithelializa-
tion of the wound and restoration of the barrier function of
the skin.73 In both skin and muscle, proliferation of ﬁbro-
blasts and endothelial cells allows matrix deposition and
angiogenesis, respectively.72e74
During the proliferative phase, the tissue monocyte/
macrophage population undergoes a phenotypic transitionThe American Journal of Pathology - ajp.amjpathol.orgthat appears to support the growth of new tissue, although
the exact mechanisms by which this transition occurs are
still being elucidated. Monocytes/macrophages of the late
inﬂammatory and early proliferative phases express abun-
dant proinﬂammatory cytokines, arginase, and VEGF,
which can promote proliferation of numerous cell types
involved in healing.6,22,25,45 As the inﬂammatory phase
declines and the proliferative phase progresses, macro-
phages in both skin and muscle decrease proinﬂammatory
cytokine expression and increase expression of anti-
inﬂammatory cytokines and growth factors, such as IL-10,
transforming growth factor (TGF)b, and insulin-like
growth factor-1.6,22,25,45 Altered cytokine and growth fac-
tor expression levels may be driven, in part, by peroxisome
proliferator-activated receptor g,19 although the causal sig-
niﬁcance and any additional transcriptional regulatory
mechanisms remain to be elucidated. Interestingly, macro-
phage phenotype in the sponge implantation model of
mouse skin wound healing is independent of STAT6, a
canonical M2a activation pathway.45
Phenotypic switching of macrophages during tissue repair
may be driven, in part, by phagocytosis of tissue debris and
apoptotic cells, although this has yet to be deﬁnitively
demonstrated in vivo. In culture, phagocytosis of apoptotic
neutrophils increases macrophage secretion of TGFb and
decreases proinﬂammatory cytokine production in response
to lipopolysaccharide (LPS) or zymosan.75 The effects of
phagocytosis of necrotic tissue, even in vitro, are less clear.
Although necrotic tissue is generally considered to be a
proinﬂammatory stimulus, phagocytosis of necrotic muscle
precursor cells by cultured macrophages has variously been
reported to either promote76 or inhibit19 TNFa production in
response to IFNg/LPS stimulation; these divergent results
may be due to use of mouse bone marrowederived macro-
phages versus human blood monocyte-derived macrophages,
or to different methods of induction of muscle cell death.
Also, in vitroedifferentiated, IFNg/LPS-activated macro-
phages are not identical to inﬂammatory-phase tissue repair
monocytes/macrophages,13 and cell culture conditions
generally do not accurately mimic the complex tissue repair
environment. Thus, caution must be used when interpreting
in vitro studies of macrophage phenotypic regulation.
In addition to potential effects of phagocytosis, macro-
phage phenotype is regulated by the biochemical milieu,
including cytokine exposure,10 and by the mechanical
properties of the environment, such as strain or substrate
stiffness.77,78 Thus, the phenotypic transition that occurs in
monocytes/macrophages from the inﬂammatory to the pro-
liferative phase may be driven, in part, by release of soluble
products from neutrophils or other cells,79 autocrine or cell-
intrinsic anti-inﬂammatory feedback mechanisms,25 and/or
changes in the mechanical, cellular, and biochemical makeup
of the granulation tissue.77,78 The relative contribution of
each of these factors and the precise molecules and signaling
pathways involved in regulation of macrophage phenotype
during in vivo tissue repair remain to be determined.1357
Novak and KohFunctionally, macrophages of the proliferative phase
appear to initiate maturation of the regenerating/repairing
tissue, rather than promoting proliferation. Although cell
proliferation and angiogenesis appear to be initiated by
monocytes/macrophages of the inﬂammatory phase, deple-
tion of macrophages during the proliferative phase of mouse
skin wound healing indicates that these macrophages sup-
port survival of endothelial cells and initiate transition of
granulation tissue into a mature scar.1 Similarly, although
cell proliferation and myoﬁber regeneration in skeletal
muscle are dependent on monocytes/macrophages of the
inﬂammatory phase, the primary effect of muscle macro-
phage depletion at later times seems to be a reduction in the
size of the regenerated myoﬁbers.19 Consistent with these
data, in human skeletal muscle after acute injury, proin-
ﬂammatory cytokines are expressed by macrophages more
frequently in regions near proliferating versus differentiating
myoblasts, whereas macrophages in proximity with differ-
entiating myoblasts more frequently express arginase-1,
CD206, and/or CD163, which are associated with anti-
inﬂammatory macrophage phenotypes.68 In culture, M2a
or M2c macrophages increase ﬁbroblast collagen production
and enhance myoblast differentiation and fusion, possibly
because of production of TGFb.19,68,80 Because in vivo
tissue repair macrophages produce TGFb during the pro-
liferative phase,13,25,45 this may be one mechanism by
which macrophages promote collagen deposition and tissue
maturation in vivo, although the importance of macrophage-
speciﬁc production of TGFb remains to be veriﬁed experi-
mentally. In total, these studies suggest that, in both skin
and skeletal muscle, macrophages present during a given
stage of healing orchestrate a transition to the next phase (ie,
macrophages of the inﬂammatory phase initiate subsequent
cell proliferation, whereas macrophages of the proliferative
phase initiate tissue maturation).
The Remodeling Phase
Finally, the remodeling phase of healing accomplishes
maturation of the regenerated or repaired tissue, including
reorganization of the vasculature and extracellular matrix/
scar tissue and hypertrophy of regenerated myoﬁbers in
skeletal muscle. Restoration of muscle force production and
myoﬁber hypertrophy continues for at least 20 days after
toxin-induced injury in mice,32,33 and human magnetic
resonance imaging data indicate that scar tissue can persist
at the repaired site for months or years after injury.81 In skin
wounds, wound closure and reepithelialization are generally
completed within approximately 1 to 2 weeks in common
experimental mouse models,1,2,6 but scar maturation
(including collagen cross-linking and replacement of
collagen III by collagen I) may take 6 months or more.82 In
addition, myoﬁbroblasts begin to undergo senescence and/
or apoptosis in the ﬁrst week after injury as granulation
tissue transforms into mature scar.83,84 The remodeling
phase also involves a controlled regression of the1358vasculature, as capillary density gradually declines toward
the level of normal tissue.74,85
Macrophages undergo further phenotypic transitions as
the proliferative phase gives way to the remodeling phase,
although the speciﬁc environmental cues that regulate this
change remain poorly deﬁned. During the remodeling phase
in mouse skin wounds, macrophages increase expression of
CD206 and CD163 relative to their earlier-phase counter-
parts, while sustaining expression of TGFb and decreasing
expression of VEGF, arginase-1, and insulin-like growth
factor-1.6,22 Interestingly, during the remodeling phase in
injured mouse muscle, macrophages exhibit decreased
expression of both proinﬂammatory and anti-inﬂammatory
cytokines,25 and also decreased expression of the M2-
associated genes CD36 and CD206 relative to macro-
phages of earlier phases of repair (unpublished data, M.L.
Novak and T.J. Koh). This deactivation appears to be
regulated, in part, by a balance of p38 and mitogen-activated
protein kinase phosphatase activity.25
The function of macrophages during the remodeling phase
of tissue repair remains unclear. In mouse models of chronic
liver ﬁbrosis, macrophages of an anti-inﬂammatory pheno-
type are required for resolution of established ﬁbrosis.5,86
However, there is no evidence that remodeling-phase mac-
rophages have a similar ﬁbrinolytic role after acute skin or
muscle injury. In fact, depletion of macrophages from mouse
skin wounds during the remodeling phase has no effect on the
amount or organization of scar tissue at 14 days after injury,1
although potential effects at later time points were not
examined. Interestingly, macrophage depletion studies sug-
gest that collagen production and scar maturation in skin
wounds are regulated by monocytes/macrophages of the in-
ﬂammatory and proliferative phases, respectively, rather than
by macrophages of the remodeling phase.1,69 In toxin-injured
mouse skeletal muscle, depletion of macrophages during the
late proliferative/early remodeling phases reduces the size of
the regenerated myoﬁbers.19 Collagen accumulation was
not examined in this study, because this model of injury
generally results in nearly complete regeneration with min-
imal ﬁbrosis and efﬁcient resolution of macrophage accu-
mulation. During ﬁbrotic skeletal muscle healing induced by
laceration injury in mice, low-level macrophage accumula-
tion persists well into the remodeling phase, but these late
macrophages exhibit a deactivated phenotype (unpublished
data, M.L. Noval and T.J. Koh) similar to that seen in toxin-
injured muscle,25 and their function remains unclear.Macrophage Dysregulation during Impaired
Healing and Fibrosis
Although monocytes/macrophages are essential to efﬁcient
healing of acute injuries to skin, skeletal muscle, and num-
erous other tissues, long-termmacrophage accumulation and/
or dysregulation of macrophage phenotype and function can
lead to tissue damage, failure to heal, and/or ﬁbrosis. Forajp.amjpathol.org - The American Journal of Pathology
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impaired healing and a prolonged proinﬂammatory macro-
phage phenotype sustained by IL-1b and TNFa,6,7,46 and
antibody-mediated reduction of macrophage accumulation in
diabetic mouse wounds accelerates wound closure.7,46 In
addition, in the sponge implantation model of skin wound
healing, macrophages from diabetic mice have reduced
ability to phagocytose apoptotic cells, and accumulation of
dead cells in diabetic wounds may contribute to healing
impairment.87 Similarly, prolonged accumulation and pro-
inﬂammatory activation of macrophages may contribute to
failed healing of chronic venous ulcers in humans.8 Proin-
ﬂammatory activation of macrophages also contributes to
myoﬁber damage in the mdx model of muscular dystrophy,9
and is associated with adverse healing outcomes after mouse
myocardial infarction88 and kidney injury.89
However, impaired healing is not always associated with
proinﬂammatory macrophage activation. Intramuscular
ﬁbrosis after laceration injury in mice is accompanied by
prolonged macrophage accumulation, but these macrophages
appear to exhibit a noninﬂammatory, deactivated phenotype
(unpublished data, M.L. Novak and T.J. Koh). Interestingly,
in toxin-injured mouse muscle, which normally regenerates
efﬁciently with minimal ﬁbrosis, macrophage deactivation
during the late proliferative/early remodeling phase is a
normal part of the healing process25; however, when mac-
rophages are prematurely deactivated because of genetic
disruption of mitogen-activated protein kinase phosphatase-
1, muscle regeneration is impaired, seemingly because of
failure to progress through the remodeling phase of repair.25
In the same injury model, disruption of integrin-b3 impairs
muscle regeneration and increases ﬁbrosis, possibly by
increasing macrophage production of TGFb, which is asso-
ciated with an M2-like phenotype.90
In summary, although macrophages certainly can con-
tribute to tissue destruction, impaired healing, and/or ﬁbrosis
in numerous situations, the culprit macrophage phenotype
appears to vary depending on the tissue type, mode of injury,
and underlying pathological characteristics. Together,
studies of macrophage function in both efﬁcient and impaired
healing demonstrate that no single macrophage activation
state can be designated as a prohealing or tissue repair
phenotype in all situations; rather, the optimal repair-
promoting macrophage phenotype will vary depending on
the stage of repair and the speciﬁc tissue microenvironment.Therapeutic Opportunities Based on
Macrophage Manipulation
Because of the central role of macrophages in orchestrating
tissue repair in health and disease, therapies aimed at modu-
lating macrophage activation may prove useful in promoting
healing and limiting ﬁbrosis. Although these therapies remain
largely hypothetical, several animal studies have provided
proof of concept for macrophage-based interventions, andThe American Journal of Pathology - ajp.amjpathol.orgsome progress has even been made in treatment of human
wounds. In diabetic mice, blockade of IL-1b, TNFa, or IL-17
ameliorates proinﬂammatory macrophage activation, up-
regulates healing-associated genes, and accelerates skin
wound healing.7,31,46 In a mouse model of muscle atrophy,
intramuscular injection of macrophage colony-stimulating
factor enhances macrophage accumulation, accelerates recov-
ery ofmuscle force production, and increases the percentage of
macrophages that express the M2-associated protein Ym-1.91
An M2 bias may also be beneﬁcial in the mdx mouse model
of muscular dystrophy, in which genetic deletion of IFNg
ameliorates the disease while increasing whole-muscle
expression of numerous M2a-related genes.9 IFNg also par-
ticipates in macrophage polarization during repair of acute
skeletal muscle injuries in mice92; however, in contrast to the
chronic mdx model, disruption of IFNg is in this case, detri-
mental to healing,92 providing further support for the notion
that the ideal repair-promoting macrophage phenotype will
differ based on the underlying pathological characteristics.
In addition to phenotypic manipulation of endogenous
macrophages, several studies have indicated that cell ther-
apy with exogenous macrophages can promote healing in a
variety of tissues, and prior ex vivo activation of these
macrophages to an M1, M2a, or other phenotype may alter
their ability to promote repair. Treatment with exogenous
M1 bone marrowederived macrophages enhances muscle
regeneration and reduces ﬁbrosis after laceration injury,
whereas nonactivated macrophages have no effect (unpub-
lished data, M.L. Novak and T.J. Koh). In contrast, in a
mouse model of kidney injury, i.v. delivery of M1 macro-
phages exacerbates tissue injury and ﬁbrosis, whereas
exogenous M2a macrophages ameliorate the disease.89
Ex vivo activation may not be necessary for macrophage
therapy to be effective in other tissues, because naïve bone
marrowederived macrophages reduce liver ﬁbrosis and
enhance regeneration after carbon tetrachloride injury in
mice,93 and application of resident peritoneal macrophages
to skin wounds of young or old mice accelerates their
closure.94 More important, in humans, hypo-osmotically
activated blood cell suspensions (which contain primarily
monocytes/macrophages and other leukocytes95,96) enhance
healing of ulcers in elderly and diabetic patients,96,97 and
reduce mortality and duration of hospitalization in patients
with infected sternal wounds after cardiac surgery.98 These
hypo-osmotically activated cells are highly phagocytic and
do not correspond to either the M1 or M2 phenotype,
because they exhibit elevated expression of IL-1b, IL-6,
TGFb, and IL-4.99,100
In summary, proof-of-concept studies have shown that
manipulating the phenotype of endogenous macrophages
may be a promising therapeutic option for improving tissue
repair.7,9,31,46,91 In addition, cell therapy with exogenous
macrophages has proved beneﬁcial to healing of a variety of
tissues, and ex vivo activation of these macrophages to an
M1, M2, or other phenotype can alter their efﬁcacy.89,96e98
More important, human wounds have proved responsive to1359
Novak and Kohmacrophage cell therapy.96e98 Further studies comparing
the efﬁcacy of different modes of macrophage activation,
along with an improved understanding of the phenotypic
fate of exogenous macrophages, may help to optimize
macrophage-based therapies for healing of different tissues
and bring these promising treatments closer to widespread
clinical reality.
Conclusions
Macrophages exhibit transitions in phenotype and function
as tissue repair progresses, although the precise factors
regulating these transitions in vivo remain poorly deﬁned. In
efﬁciently healing injuries, macrophages present during a
given stage of repair appear to orchestrate transition into the
next phase; as such, macrophages of different phases can
promote debridement of the injury site, cell proliferation,
angiogenesis, collagen deposition, and matrix remodeling.
However, dysregulated macrophage function can contribute
to failed healing or ﬁbrosis in several pathological situa-
tions. Modulation of macrophage function may provide
promising therapies to promote tissue repair.
Many open questions remain regarding the mechanisms
underlying the reciprocal regulation of macrophage function/
phenotype and the tissue repair environment. The question of
in situ conversion versus sequential recruitment of Ly6Chi
and Ly6Clow monocytes in tissues other than cardiac and
skeletal muscle has not been systematically investigated. In
addition, although monocytes/macrophages are certainly
able to phagocytose apoptotic neutrophils in vitro, a
requirement for monocytes/macrophages for neutrophil
clearance in vivo has not been deﬁnitively established.
Similarly, although phagocytosis of apoptotic neutrophils or
necrotic tissue induces phenotypic changes in cultured
macrophages, the relative importance of phagocytosis versus
other factors, such as autocrine feedback mechanisms or the
changing mechanical and biochemical environment, in
regulating macrophage phenotype in vivo remains to be
determined. Furthermore, although in vitro studies have
identiﬁed a myriad of potential factors produced by macro-
phages that may promote cell proliferation and tissue matu-
ration, few studies have ascertained the importance of
macrophage-speciﬁc production of these factors during
in vivo tissue repair. Finally, the function of macrophages
during the remodeling phase of healing, and particularly
whether these macrophages may have ﬁbrinolytic activity,
remains uncertain. An improved understanding of macro-
phage activation and its regulation during tissue repair may
help to develop new therapies in which manipulation of
macrophage function can be used to improve healing.
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